Enabling T cell immunotherapy 

Intracellular delivery is the most problematic step in cell-based immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor immune cells with minimal perturbation.

Learn More
Enabling T cell immunotherapy Graphic
Benefits of the µVS Delivery System™
Simple Check mark


Easy-to-integrate with existing research, clinical and commercial workflows with standard reagents.

Scale Check mark


µVS devices can be readily manufactured at scales of >2K devices per day.

Speed Check mark


Cells are processed at 1~5M per second and soon to be >50M cells per second.

Throughput Check mark


Each 5 x 10 mm device can process >50M cells with a >1B cell device in development.

Yield Check mark


µVS is optimised to yield the maximum amount of recovered, viable and modified cells.

Quality Check mark


µVS processing results in minimal perturbation of the T cell state for high quality cells.

State of the µVS Delivery System™

The µVS Delivery System™ is currently available for Research Use Only. A clinical system is in development and will be regulated as a tool for biologics manufacturing. Both systems are developed in an ISO 13485-compliant manner and all materials in the flow path are medical-grade or USP Class VI implantable-grade. µVS devices for high-throughput screening of small volumes based on the well plate format are also in development.

Learn More


Interested in using the µVS Delivery System™?

Equipment Trials

Lease the µVS Delivery SystemTM for 6-months

Ask Us

Research Services

Have us develop a kit for another cell type or construct

Ask Us


Tell us how we can help you reach your goals

Ask Us

Have questions? Send us a message

You can also reach us by emailing hello@indeelabs.com